Many scientists-turned-CEOs paradoxically abandon scientific principles when it comes to commercializing their innovations.
Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.
Jay Bhattacharya will become the latest leader of the CDC on an acting basis, days after Jim O’Neill stepped aside.
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
PitchBook’s 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with ...
Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...
Once fully operational, the Pennsylvania site will employ more than 500 people and make cell therapies for thousands of patients a year.
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
In the incredibly hot obesity drug space, with more than 700 clinical trials ongoing, Verdiva Bio and MitoRx leaders discuss how next-generation therapies are targeting lean muscle preservation, ...
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and ...
After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out ...
Johns Hopkins’ Thomas Hartung discusses how drug discovery and development will change under evolving regulatory policies ...
The FDA’s drug review process can often be "unpredictable," and review teams typically “differ greatly” in what they ask of drug sponsors, Sen. Bill Cassidy said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results